Guest guest Posted February 26, 2003 Report Share Posted February 26, 2003 Here is an interesting new product - Pat Father of Cameron 2 and Claire 4mo both wcf _________ The news article is ( BW)(MA-DYAX-CORP)(DYAX) Updated Information Regarding Dyax's Presentation at Today's BIO CEO & Investor Conference Business Editors/Health/Medical Writers BIO CEO & Investor Conference 2003 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2003--Dyax Corp.'s presentation at the 5th Annual BIO CEO & Investor Conference will be held this morning at 9:30 a.m. Eastern Time in the East Foyer at the Waldorf Astoria instead of 2:00 p.m. tomorrow as previously announced. In addition, Henry Blair, Chairman and Chief Executive Officer of Dyax, will be the presenter not Jack , the company's Senior Vice President of Corporate Development and Business Operations. The conference is being held at the Waldorf Astoria in New York City from February 25 through February 27, 2003. The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the Company website at http://www.dyax.com. The 25-minute presentation will also be available on the Company's website for a limited period of time following the conference. Dyax Corp. Dyax Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products. The Company uses its core patented phage display technology to identify a broad range of recombinant protein, peptide, and fully human monoclonal antibody compounds that bind with high affinity and specificity to targets of interest, with the objective of selecting those compounds with the greatest potential for advancement into clinical development. Dyax currently has two small proteins in phase II clinical trials. DX-88 is being studied for the treatment of hereditary angioedema and for use during cardiopulmonary bypass surgery, while DX-890 is being studied for the treatment of cystic fibrosis. Dyax leverages its technology broadly through revenue generating licenses and collaborations in therapeutics and in non-core areas of affinity separations, diagnostic imaging, and research reagents. Through its subsidiary, Biotage, Inc., Dyax develops, manufactures and sells chromatography separations systems and products to pharmaceutical companies worldwide for drug discovery and purification. For more information on Dyax Corp., please visit the Company's website at www.dyax.com. Dyax and the Dyax logo are registered trademarks of Dyax Corp. Biotage is a trademark of Biotage, Inc., a Dyax subsidiary. --30--GK/bo* CONTACT: Dyax Corp. Sondra Henrichon, 617/250-5839 shenrichon@... The product and website are: http://www.dyax.com/pipeline/dx890.asp DX-890 Using phage display, Dyax discovered DX-890, a small protein thought to have the potential to reduce or eliminate lung damage caused by human neutrophil elastase (hNE). HNE is implicated as having a role in many other chronic lung diseases, especially bronchitis and emphysema. DX-890 is currently formulated as an aerosol and delivered by inhalation. Indication 1 - Cystic Fibrosis Cystic fibrosis (CF) is a fatal genetic disease afflicting about 50,000 people in the United States and Europe. CF results in abnormal ion transport in cells, causing the production of thick mucus which clogs the lungs and other organs. Individuals with CF also experience a reduction in lung function which might, in part, be due to local expression of the enzyme human neutrophil elastase (hNE). Conventional treatments for CF, including drugs that break up excessive mucus and antibiotics to fight infections, have greatly extended the lives of CF patients. Still, life expectancy is only thirty years. Dyax's potent in vitro HNE inhibitor, DX-890, may have the potential to reduce or eliminate lung damage in CF thought to be caused by HNE. Alternate Indications Under Consideration Dyax is evaluating the use of DX-890 in other diseases where HNE is thought to be involved. One of these diseases, alpha1 anti-trypsin (A1AT) deficiency, is a genetic disorder affecting nearly 100,000 patients in the U.S. Individuals with this deficiency experience lung and liver damage. The existing therapy, which augments low levels of the A1AT protein, is in short supply and is produced from human plasma. DX-890 may be an effective alternative therapy to reduce or prevent the lung damage in these patients. Other indications we are considering include emphysema, affecting two million people in the U.S., and ulcerative colitis. Ulcerative colitis is a painful, inflammatory bowel disease affecting about 400,000 people in the U.S. Patients with this illness often require very potent immunosuppressive therapy. DX-890 Clinical Status Normal Volunteers In January 2001, Dyax and its European collaborator, Debiopharm SA, completed a multi-site Phase Ib clinical trial evaluating DX-890 in normal human volunteers in France. In this study, DX-890 was well-tolerated and shown to be active with fluids obtained from the lungs of healthy test subjects. Cystic Fibrosis A Phase II trial for DX-890 was conducted in France and Italy, testing two escalating dose levels in 24 adult CF patients. Although full results are not yet available, preliminary results suggest that DX-890 is well tolerated and inhibits HNE in the sputum of these patients. Dyax and Debiopharm are encouraged by these preliminary findings and are planning for future trials in this patient population. --- Outgoing mail is certified Virus Free. Checked by AVG anti-virus system (http://www.grisoft.com). Version: 6.0.458 / Virus Database: 257 - Release Date: 2/24/2003 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.